Schizophrenia.com
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
News
Nirvana
October 9, 2024, 8:44pm
1
5 Likes
Related topics
Topic
Replies
Views
Activity
AbbVie to tap Vraylar messaging lessons, but also create a new position to promote key psychiatric drug from Cerevel buy
News
2
301
December 8, 2023
AbbVie (ABBV) Falls 13% After Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
News
3
116
November 11, 2024
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
News
0
40
January 31, 2025
Emraclidine delivers positive results in phase Ib trial
News
0
188
December 28, 2023
Precision Medicine and Novel Approaches on Cusp of Breaking Through in Psychiatry
News
6
274
June 4, 2024